Recurrent or Metastatic Head and Neck Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent or Metastatic Head and Neck Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent or Metastatic Head and Neck Cancer Research. Learn more about our innovative pipeline today! @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

* June 2024:- BioNTech SE- An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT).
* June 2024:- Janssen Research & Development, LLC- A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
* June 2024:- AVEO Pharmaceuticals Inc.- A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN).
* June 2024:- Exelixis- A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
* June 2024:- Lyvgen Biopharma Holdings Limited- A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment.
* DelveInsight's Recurrent or Metastatic Head and Neck Cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck Cancer treatment.
* The leading Recurrent or Metastatic Head and Neck Cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
* Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as Durvalumab, Cetuximab, RiMO-301, Buparlisib & Paclitaxel, Oral Decitabine, Methotrexate, Afatinib, OSI-774, Cisplatin, Epacadostat, and others.

Stay informed about the cutting-edge advancements in Recurrent or Metastatic Head and Neck Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Recurrent or Metastatic Head and Neck Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Recurrent or Metastatic Head and Neck Cancer Emerging Drugs Profile

* Xevinapant: Merck

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive 188 million upfront and up to 710 million in regulatory and commercial milestones, as well as royalty payments

* SI B001: Sichuan Baili Pharmaceutical

SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR times EGFR homodimers, the formation of EGFR times HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.

Learn more about Recurrent or Metastatic Head and Neck Cancer Drugs opportunities in our groundbreaking Recurrent or Metastatic Head and Neck Cancer Research and development projects @ Recurrent or Metastatic Head and Neck Cancer Unmet Needs [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous

Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Recurrent or Metastatic Head and Neck Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Recurrent or Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

* Coverage- Global
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
* Recurrent or Metastatic Head and Neck Cancer Therapies- Durvalumab, Cetuximab, RiMO-301, Buparlisib & Paclitaxel, Oral Decitabine, Methotrexate, Afatinib, OSI-774, Cisplatin, Epacadostat, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Recurrent or Metastatic Head and Neck Cancer Pipeline on our website @ Recurrent or Metastatic Head and Neck Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Recurrent or Metastatic Head and Neck cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Recurrent or Metastatic Head and Neck cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lenvatinib: Eisai Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SI B001: Sichuan Baili Pharmaceutical
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Revdofilimab: AbbVie
* Drug profiles in the detailed report.....
* Early Stage Products (Preclinical)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Recurrent or Metastatic Head and Neck cancer Key Products
* Recurrent or Metastatic Head and Neck cancer- Unmet Needs
* Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
* Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
* Recurrent or Metastatic Head and Neck cancer Analyst Views
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=recurrent-or-metastatic-head-and-neck-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.